Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.

被引：1
|
作者：
Bikkasani, Krishna
Qin, Qian
Lin, Justin
Galsky, Matt D.
Liaw, Bobby Chi-Hung
Oh, William K.
Tsao, Che-Kai
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA
[2] CUNY, Sch Med, New York, NY 10031 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.184
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
184
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients
    Carton, E.
    Noe, G.
    Huillard, O.
    Golmard, J. L.
    Giroux, J.
    Cessot, A.
    Peyromaure, M.
    Zerbib, M.
    Narjoz, C.
    Thomas, A.
    Vidal, M.
    Goldwasser, F.
    Blanchet, B.
    Alexandre, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S491 - S491
  • [42] Lipidomic profiling in patients with heavily pretreated castration-resistant prostate cancer.
    Cattrini, Carlo
    Manfredi, Marcello
    Barboro, Paola
    Ghirimoldi, Marco
    Mennitto, Alessia
    Martini, Veronica
    Biello, Federica
    D'Avanzo, Francesca
    Platini, Francesca
    Maggiora, Paola Maria
    Branni, Carmen
    Rua, Alessia
    Diprima, Santo
    Tassone, Andrea
    Gobbato, Simone
    Stella, Arianna
    Zanardi, Elisa
    Pinato, David James
    Boccardo, Francesco
    Gennari, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide
    Gandhy, Shruti U.
    Karzai, Fatima
    Marte, Jennifer L.
    Bilusic, Marijo
    McMahon, Sheri
    Strauss, Julius
    Couvillon, Anna
    Williams, Monique
    Hankin, Amy
    Steinberg, Seth M.
    Figg, William Douglas
    Arlen, Philip M.
    Dahut, William L.
    Gulley, James L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer
    Zafar Malik
    Heather Payne
    Jawaher Ansari
    Simon Chowdhury
    Mohammad Butt
    Alison Birtle
    Santhanam Sundar
    Chinnamani Vee Eswar
    Simon Hughes
    Amit Bahl
    Advances in Therapy, 2013, 30 : 1041 - 1066
  • [45] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] New treatment options for patients with metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    CANCER TREATMENT REVIEWS, 2012, 38 (05) : 340 - 345
  • [47] Chemotherapy in frail elderly patients with metastatic castration-resistant prostate cancer?
    Molina-Garrido, Maria-Jose
    Guillen-Ponce, Carmen
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (12) : 579 - 580
  • [48] Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer
    J. Wang
    T. R. McGuire
    H. C. Britton
    J. K. Schwarz
    F. R. Loberiza
    J. L. Meza
    J. E. Talmadge
    Clinical & Experimental Metastasis, 2015, 32 : 111 - 124
  • [49] Predictors of overall survival in patients with metastatic castration-resistant prostate cancer
    Markova, A. S.
    Polikarpova, S. B.
    Kamolov, B. Sh.
    Gridneva, Ya. V.
    Kalinin, S. A.
    Peters, M. V.
    Matveev, V. B.
    ONKOUROLOGIYA, 2015, 11 (02): : 77 - 84
  • [50] Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer
    Wang, J.
    McGuire, T. R.
    Britton, H. C.
    Schwarz, J. K.
    Loberiza, F. R., Jr.
    Meza, J. L.
    Talmadge, J. E.
    CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (02) : 111 - 124
12345